AU2004275718B2 - Quinazoline potassium channel inhibitors - Google Patents

Quinazoline potassium channel inhibitors Download PDF

Info

Publication number
AU2004275718B2
AU2004275718B2 AU2004275718A AU2004275718A AU2004275718B2 AU 2004275718 B2 AU2004275718 B2 AU 2004275718B2 AU 2004275718 A AU2004275718 A AU 2004275718A AU 2004275718 A AU2004275718 A AU 2004275718A AU 2004275718 B2 AU2004275718 B2 AU 2004275718B2
Authority
AU
Australia
Prior art keywords
alkyl
methoxy
ring
compounds
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004275718A
Other languages
English (en)
Other versions
AU2004275718A1 (en
Inventor
Richard Isaacs
B. Wesley Trotter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2004275718A1 publication Critical patent/AU2004275718A1/en
Application granted granted Critical
Publication of AU2004275718B2 publication Critical patent/AU2004275718B2/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: Refer to Publication History
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: Refer to Publication History
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK SHARP & DOHME CORP.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2004275718A 2003-09-23 2004-09-17 Quinazoline potassium channel inhibitors Ceased AU2004275718B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50513903P 2003-09-23 2003-09-23
US60/505,139 2003-09-23
PCT/US2004/030483 WO2005030217A1 (en) 2003-09-23 2004-09-17 Quinazoline potassium channel inhibitors

Publications (2)

Publication Number Publication Date
AU2004275718A1 AU2004275718A1 (en) 2005-04-07
AU2004275718B2 true AU2004275718B2 (en) 2008-02-07

Family

ID=34392984

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004275718A Ceased AU2004275718B2 (en) 2003-09-23 2004-09-17 Quinazoline potassium channel inhibitors

Country Status (8)

Country Link
US (1) US7906521B2 (cg-RX-API-DMAC7.html)
EP (1) EP1667685B1 (cg-RX-API-DMAC7.html)
JP (1) JP4719681B2 (cg-RX-API-DMAC7.html)
CN (1) CN1856310A (cg-RX-API-DMAC7.html)
AT (1) ATE549024T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004275718B2 (cg-RX-API-DMAC7.html)
CA (1) CA2539476C (cg-RX-API-DMAC7.html)
WO (1) WO2005030217A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0416730D0 (en) 2004-07-27 2004-09-01 Novartis Ag Organic compounds
CA2575003C (en) 2004-07-29 2010-02-16 Merck & Co., Inc. Potassium channel inhibitors
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
BRPI0608343A2 (pt) * 2005-03-09 2016-10-04 Merck & Co Inc composto, composição farmacêutica, e, métodos para tratamento ou controle de uma doença ou condição, para intensificação da qualidade do sono, para aumento de sono rem e do sono de onda lenta, para diminuição da fragmentação de padrões do sono, para intensificação de cognição, para aumento da retenção de memória, e, para tratamento, controle, melhora ou redução do risco de esquizofrenia em um paciente mamífero em necessidade destes
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
WO2007098386A1 (en) * 2006-02-17 2007-08-30 Janssen Pharmaceutica N.V. Pyrazolylquinazolinones as potassium channel openers
DE102006019589A1 (de) * 2006-04-27 2007-10-31 Sanofi-Aventis Deutschland Gmbh Inhibitoren des TASK-1 und Task-3 Ionenkanals
WO2008112320A1 (en) * 2007-03-15 2008-09-18 The Trustees Of The University Of Pennsylvania Inhibition of ion channel function
CA2692783A1 (en) * 2007-07-10 2009-01-15 Merck Sharp & Dohme Corp. Quinazolinone t-type calcium channel antagonists
CN101654441B (zh) * 2008-08-19 2012-10-03 信谊药厂 抗凝化合物、组合物及其用途
WO2010088195A1 (en) * 2009-01-30 2010-08-05 Boehringer Ingelheim International Gmbh Azaquinazolinediones useful as chymase inhibitors
PT2473487T (pt) 2009-09-03 2017-01-04 Bristol Myers Squibb Co Quinazolinas como inibidores dos canais iónicos de potássio
CN103130730B (zh) * 2011-11-24 2015-04-08 南开大学 喹唑啉类衍生物及其制备方法、抗hiv活性和抗tmv活性
HUE041418T2 (hu) * 2013-08-29 2019-05-28 Kyoto Pharma Ind Aromás vegyületek és alkalmazásuk csont metabolizmushoz kapcsolódó rendellenességek kezelésére
EP3043790B1 (en) 2013-09-11 2021-05-26 The Administrators of the Tulane Educational Fund Novel anthranilic amides and the use thereof
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155110A (en) * 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1311573A (en) 1970-04-27 1973-03-28 Hisamitsu Pharmaceutical Co Quinazolinedione derivatives
GB1491510A (en) * 1973-12-14 1977-11-09 Hisamitsu Pharmaceutical Co 1-nitrophenylquinazoline-2,4(1h,3h)-diones
JPS6020387B2 (ja) * 1975-12-26 1985-05-21 久光製薬株式会社 新規なキナゾリン誘導体の製造法
LU74369A1 (cg-RX-API-DMAC7.html) 1976-02-18 1977-09-12
US5891904A (en) * 1992-09-14 1999-04-06 Wolf-Georg Forssmann Use of inhibitors of phosphodiesterase IV
ATE178210T1 (de) * 1992-09-14 1999-04-15 Forssmann Wolf Georg Prof Dr Neue verwendung von inhibitoren der phosphodiesterase iv
HUT76640A (en) * 1995-08-17 1997-10-28 Chinoin Gyogyszer Es Vegyeszet Compounds of pharmaceutical activity cyclic amide derivatives, pharmaceutical compositions containing them, process for producing them and their use
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6037345A (en) * 1998-01-13 2000-03-14 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazolinedione and pyridopyrimidinedione derivatives
US6870055B2 (en) 2000-09-20 2005-03-22 Merck & Co., Inc. Isoquinolinone potassium channels inhibitors
CN1988907B (zh) 2004-06-01 2010-12-22 弗吉尼亚大学专利基金会 癌瘤及血管生成的双重小分子抑制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155110A (en) * 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition

Also Published As

Publication number Publication date
CA2539476A1 (en) 2005-04-07
US20070054894A1 (en) 2007-03-08
CN1856310A (zh) 2006-11-01
JP4719681B2 (ja) 2011-07-06
JP2007506742A (ja) 2007-03-22
WO2005030217A1 (en) 2005-04-07
CA2539476C (en) 2011-04-19
AU2004275718A1 (en) 2005-04-07
EP1667685B1 (en) 2012-03-14
EP1667685A4 (en) 2009-04-29
US7906521B2 (en) 2011-03-15
EP1667685A1 (en) 2006-06-14
ATE549024T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
US8338449B2 (en) Isoquinolinone potassium channel inhibitors
AU2004275719B2 (en) Quinoline potassium channel inhibitors
AU2004289186B2 (en) Isoquinolinone potassium channel inhibitors
AU2004275718B2 (en) Quinazoline potassium channel inhibitors
AU2004276267B2 (en) Isoquinolinone potassium channel inhibitors
US7691879B2 (en) Isoquinoline potassium channel inhibitors
AU2004276268B2 (en) Isoquinoline potassium channel inhibitors
AU2004276238B2 (en) Isoquinolinone potassium channel inhibitors
AU2004276237B2 (en) Quinoline potassium channel inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND PATENTEE NAME FROM MERCK & CO., INC. TO MERCK SHARP & DOHME CORP.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired